Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study-Reference-Cited by-同舟云学术

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

Published:2013-10-11 Issue:6 Volume:58 Page:1918-1929
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Fried Michael W.¹,Buti Maria²,Dore Gregory J.³,Flisiak Robert⁴,Ferenci Peter⁵,Jacobson Ira⁶,Marcellin Patrick⁷,Manns Michael⁸,Nikitin Igor⁹,Poordad Fred¹⁰,Sherman Morris¹¹,Zeuzem Stefan¹²,Scott Jane¹³,Gilles Leen¹⁴,Lenz Oliver¹⁴,Peeters Monika¹⁴,Sekar Vanitha¹⁵,De Smedt Goedele¹⁴,Beumont-Mauviel Maria¹⁴

Affiliation:

1. University of North Carolina at Chapel Hill; NC

2. Hospital Vall d'Hebron and Ciberehd del Instituto Carlos III; Barcelona Spain

3. St Vincent's Hospital, Sydney, Australia and Kirby Institute; University of New South Wales; Sydney Australia

4. Medical University of Bialystok; Bialystok Poland

5. Allgemeines Krankenhaus der Stadt Wien; Vienna Austria

6. Weill Cornell Medical College; Cornell NY

7. Hopital Beaujon; Clichy; Paris France

8. Medizinische Hochschule Hannover; Hannover Germany

9. Russian State Medical University; Moscow Russia

10. University of Texas Health Science Center; San Antonio TX

11. Toronto General Hospital; Toronto Ontario Canada